Positron EPS
The Earnings per Share (EPS) of Positron (POSC) as of Jul 20, 2026 is -0.28 USD.
Get this data via API
Financial Data API
EPS
-0.28USD
Last updated:
Earnings per Share (EPS) of Positron is 2026 -0.28 USD. Earnings per Share (EPS) of Positron was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Positron Stock analysis
What does Positron do? Positron Corp is a company in the medical technology industry specializing in the development of PET (positron emission tomography) systems and solutions. The company was founded in 1983 as Positron Corporation with headquarters in Houston, Texas, USA. Initially focused on research and development of technologies for radiation therapy, the company shifted its focus to PET imaging and became a pioneer in the field. Positron Corp's business model is based on selling PET systems and related solutions and services to medical facilities and organizations. The company offers both stationary and mobile systems for various applications such as cancer diagnostics. Positron Corp is divided into different divisions specializing in different areas of PET technology, including the development, production, and distribution of PET modules, systems, and software solutions. The flagship product of Positron Corp is the Total-body PET module, which enables complete imaging of the human body and is unique in the medical field. The module was designed to meet the need for whole-body imaging in cancer diagnostics and offers patients a non-invasive way to monitor cancer cells and metastases. In addition to the Total-body PET module, the company also offers specialized solutions for various areas of PET imaging, including a portable PET scanner suitable for use in emergency rooms or intensive care units. Another area of Positron Corp is the development and production of radiation therapy products. The company has developed a range of radiopharmaceuticals that can be used in cancer treatment, including radioisotopes such as fluorine-18, used for labeling molecules in cancer diagnostics, and yttrium-90, used in radiation therapy for the treatment of liver tumors. To ensure that its products remain at the forefront of technology, Positron Corp is heavily involved in research and development. The company collaborates closely with leading research and development companies to develop innovative solutions and technologies that meet the demands of the medical technology industry. Overall, Positron Corp has established itself as a key player in the medical technology industry, developing innovative solutions and technologies for PET imaging and radiation therapy. The company is committed to improving the standard of medical diagnostics and treatment, contributing to the improvement of healthcare. Positron is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Positron stock
Earnings per Share (EPS) of Positron is -0.28 USD in 2026.
Access this data via the Eulerpool API
Income Statement — Positron
All Key Metrics — Positron
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth